Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Defence Therapeutics ( (TSE:DTC) ) has issued an announcement.
Defence Therapeutics has closed a private placement of 17,445,455 units at $0.55 per unit, raising gross proceeds of approximately $9.6 million. Each unit consists of one common share and one warrant exercisable at $0.65 for 24 months, with institutional investors receiving additional units as corporate finance fees under a sharing agreement.
The company plans to use the new capital to advance its antibody-drug conjugate and radiopharmaceutical programs, pursue strategic partnerships, and fund general working capital. The financing, which involved no finder’s fees and is subject to customary resale restrictions, strengthens Defence’s balance sheet as it seeks to progress its oncology pipeline and reinforce its position in precision drug delivery.
The most recent analyst rating on (TSE:DTC) stock is a Hold with a C$0.62 price target. To see the full list of analyst forecasts on Defence Therapeutics stock, see the TSE:DTC Stock Forecast page.
Spark’s Take on TSE:DTC Stock
According to Spark, TipRanks’ AI Analyst, TSE:DTC is a Neutral.
The score is primarily constrained by very weak financial performance (no revenue, ongoing losses/cash burn, and negative equity). Technicals are mixed with short-term stabilization but longer-term weakness, and valuation provides limited support due to negative earnings and no dividend yield.
To see Spark’s full report on TSE:DTC stock, click here.
More about Defence Therapeutics
Defence Therapeutics is a publicly traded biotechnology company focused on making cancer treatments more effective and safer. Leveraging its proprietary Accum precision intracellular drug delivery platform, the company aims to boost the potency of antibody-drug conjugates and other complex biologics at lower doses, targeting reduced side effects and wider access to advanced therapies.
YTD Price Performance: -13.89%
Average Trading Volume: 53,575
Technical Sentiment Signal: Sell
Current Market Cap: C$35.57M
Find detailed analytics on DTC stock on TipRanks’ Stock Analysis page.